CD8A and neoplasm: The MC-38 model provided a unique opportunity to rigorously compare tumor-unrelated and tumor-specific help in neoantigen vaccination, as we and others recently identified CD8+ and CD4+ T cell neo-epitopes on this highly mutated, MHC class II-negative tumor cell line.